All In Biotech

NDA 021324 · Padagis US

Entocort Ec

Budesonide · Oral · Corticosteroid

Priority review

Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Oct 2, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

40,657

31,583 serious, 3,109 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 17, 2026.

Budesonide delayed-release capsules are a corticosteroid indicated for: Treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, in patients 8 years and older. ( 1.1 ) Maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 ) 1.1 Treatment of Mild to Moderate Active Crohn’s Disease Budesonide delayed-release capsules are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. 1.2 Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease Budesonide delayed-release capsules are indicated for the maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months in adults.

Mechanism: Budesonide is an anti-inflammatory corticosteroid and has a high glucocorticoid effect and a weak mineralocorticoid effect, and the affinity of budesonide to glucocorticoid receptors, which reflects the intrinsic potency of the drug, is about 200-fold that of cortisol and 15-fold that of prednisolone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ENTOCORT EC · BUDESONIDE 3MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,894
  • dyspnoea4,577
  • off label use4,445
  • asthma3,630
  • fatigue2,606
  • condition aggravated2,492
  • headache2,438
  • diarrhoea2,387
  • cough2,245
  • pneumonia2,245
  • nausea2,110
  • wheezing2,025

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005220
2006195
2007197
2008282
2009292
2010320
2011533
2012736
2013782
2014978
20151,346
20161,591
20171,682
20182,259
20192,940
20203,524
20213,719
20224,002
20233,975
20244,117
20254,002
20262,827

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: Padagis US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.